BASHH UK guidelines for the management of syphilis 2024
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index; 53 of the 183 sources its claims cite were checked for support.
Abstract
The 2024 UK guidelines for the management of syphilis are in line with current evidence and practice within the UK. Key updates are detailed at the start of the article. These guidelines are accompanied by the first UK guidelines for the management of syphilis in pregnant people and children, 2024.
Overview
CoChat Summary
TL;DR
The 2024 BASHH UK guidelines update recommendations for diagnosing and managing syphilis in people aged 16 and over in UK specialist sexual health services, with key changes including licensed benzathine penicillin with lidocaine, withdrawal of macrolides due to resistance, ceftriaxone as a penicillin alternative, expanded PCR use, and revised serology, lumbar puncture and treatment-interruption advice. They are accompanied by the first UK guidelines for syphilis in pregnant people and children.
Key findings
- Macrolides are no longer recommended for syphilis treatment due to antimicrobial resistance (point mutation at A2058G or A2059G in the 23S rRNA gene) and poor placental/blood–brain barrier penetration; benzathine penicillin G remains first-line, with penicillin resistance never reported.
- Benzathine penicillin diluted with lidocaine is now licensed in the UK and is the recommended preparation; ceftriaxone is an alternative appropriate in most cases where penicillin cannot be used.
- Routine CSF assessment in patients without symptomatic disease is not recommended (1A); CSF examination is indicated with clinical neurological involvement except ophthalmic or otological syphilis, where it is rarely useful (1C). CSF RPR is 51%–82% sensitive and 82%–100% specific; CSF TPHA titre >1:320 is sensitive and specific for neurosyphilis.
- Epidemiology cited: England 2019 had 7982 infectious syphilis cases, 5875 (74%) in GBMSM, 43% of whom were living with HIV; by 2019 diagnoses in women rose 135% to 597 and doubled in men to 1016. Approximately one-third of sexual contacts of infectious syphilis develop disease (transmission rates 10%–60%), and 46%–60% of contactable partners of early syphilis cases are infected.
- Treatment interruption: a single 2.4 MU benzathine penicillin G dose gives treponemicidal levels for 2–4 weeks, so subsequent doses within 14 days of the previous dose do not require restarting; for neurosyphilis, interruption >24 h requires restarting the course (1B).
Methods
- Guideline development by a writing group following the BASHH Framework for Guideline Development, with an equality impact assessment using the NICE tool, CEG review, 2-month public consultation on the BASHH website, and piloting by target users and the BASHH public panel.
- Systematic literature review of Medline, Embase and the Cochrane library for English-language publications January 2014–December 2020, using 11 defined search strings covering partner notification, treatment, serology, PCR, point-of-care tests, neurosyphilis diagnosis, typing and whole genome sequencing; previous UK and US guidelines were also reviewed.
- Recommendations are graded (e.g. 1A–2D) and cover diagnosis, treatment regimens, partner notification, follow-up and auditable outcomes (e.g. 97% standards for RPR titre at treatment, treatment adherence and contact action documentation; 65% for RPR titre at 6 months).
Limitations
- Stated: robust evidence for optimal management of complications and tertiary syphilis is lacking, so recommendations rest mainly on laboratory considerations, biological plausibility, expert opinion, case studies and clinical experience; there is very little evidence on the recommended duration of sexual abstinence after treatment.
- Stated: no diagnostic gold standard for neurosyphilis means studies use differing definitions, limiting the strength of the evidence base; evidence for T. pallidum PCR in neurosyphilis is weak (small, heterogeneous studies).
- Stated: the recommendations may not be appropriate in all clinical situations and decisions must rest on clinician judgement, individual patient circumstances and available resources; the guidelines target people aged 16+ in UK specialist STI care, though principles should be adopted across care levels.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Valid · 15 Not valid · 37 Not checked · 16 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV infection does not appear to affect the mucocutaneous manifestations of secondary syphilis.22,23”
What the sources say
- Not checked — no full text of the sourcecites [22] source
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Introduction says there is little to suggest that dermatologic manifestations of secondary syphilis are more striking in people with HIV, supporting the claim's qualified point about skin manifestations. It does not make the same comparison for mucosal lesions or establish that HIV has no effect on mucocutaneous manifestations overall. (LLM, conf=0.84)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Untreated, 25% of patients will develop signs of secondary syphilis approximately 3–10 weeks after the appearance of the initial chancre .23,24”
What the sources say
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
The Introduction says secondary-stage lesions generally appear 4–10 weeks after primary lesions first appear, broadly supporting the timing but not the stated 3–10 weeks. Its ‘Early Latency, Relapses, or Recurrent Secondary Eruptions’ section applies the 25% figure to patients whose infection had become latent and who experienced a recurrence within 12 months, not to patients first developing secondary syphilis. (LLM, conf=0.90)
- Not matchedcites [24]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A positive IgM result may be useful if primary or congenital syphilis is suspected.”
What the sources say
- Not checked — no full text of the sourcecites [49] source
- Supportedcites [50] source
The Introduction (page not provided) says early IgM detection could help diagnose early syphilis and reports that European guidelines consider IgM testing useful in assessing newborns. This supports the claim’s cautious wording, though the paper notes that a negative IgM result cannot exclude congenital syphilis and that evidence for its utility in newborns is limited. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [51] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Rapid point-of-care tests using finger prick blood samples are useful for on-site testing in outreach settings, provided positive results are confirmed by laboratory tests.”
What the sources say
- Partly supportedcites [52] sourceExperimental — accuracy not yet measured
The Note section (page not provided) says rapid point-of-care syphilis tests use finger-prick whole blood and enable same-day testing and treatment. It does not specifically establish their usefulness in outreach settings or say that positive finger-prick results must be confirmed by laboratory tests; its discussion of combining test results concerns syphilis diagnosis generally. (LLM, conf=0.86)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A positive CSF TPHA test is highly sensitive for neurosyphilis”
What the sources say
- Partly supportedcites [73] sourceExperimental — accuracy not yet measured
The Results report that CSF TP.PA was reactive in all 16 patients classified as having neurosyphilis, and Table 3 shows MHA-TP was reactive in 15 of 16. The paper does not report sensitivity for a CSF TPHA test: its Introduction mentions only a TPHA index, while the measured tests were TP.PA and MHA-TP. Thus the claim is consistent with the paper’s findings for related tests, but attributes them to a different test. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
60 more claims · 24 with their cited sources checked
Create a free account to see all 107 claims and every source verdict.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 24
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 2 International Journal of STD & AIDS 0(0)
“General paresis: this is a progressive dementing illness that occurs 10–25 years after infection secondary to cortical neuronal loss.”
§ 2 International Journal of STD & AIDS 0(0)
“• General paresis 10–20 years Cortical neuronal loss”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 2 International Journal of STD & AIDS 0(0)
“Meningovascular syphilis typically occurs 5–10 years after infection (but sometimes earlier).”
§ 2 International Journal of STD & AIDS 0(0)
“Meningovascular 0–7 years Focal arteritis inducing infarction/meningeal inflammation”
Citations
Cites
Peeling, R. W., Mabey, D., Kamb, M. L., Chen, X.-S., Radolf, J. D., & Benzaken, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.73 · Cited by 664
Syphilis: Review with Emphasis on Clinical, Epidemiologic, and Some Biologic Features
Singh, A. E., & Romanowski, B. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.187 · Cited by 638
LaFond, R. E., & Lukehart, S. A. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.29-49.2006 · Cited by 634
Lukehart, S. A., Hook, E. W., Baker-Zander, S. A., Collier, A. C., Critchlow, C. W., & Handsfield, H. H. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-11-855 · Cited by 603 · cited 1×
“83 · If treatment for neurosyphilis is interrupted for more than 24 h the course should be re-started; this is because of the need to maintain continuous CSF treponemicidal levels of treatment throughout the course.”
BackgroundRolfs, R. T., Joesoef, M. R., Hendershot, E. F., Rompalo, A. M., Augenbraun, M. H., Chiu, M., Bolan, G., Johnson, S. C., French, P., Steen, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707313370504 · Cited by 550
Marra, C. M., Maxwell, C. L., Smith, S. L., Lukehart, S. A., Rompalo, A. M., Eaton, M., Stoner, B. P., Augenbraun, M., Barker, D. E., Corbett, J. J., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/381227 · Cited by 491
Hook, E. W., & Marra, C. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204163261606 · Cited by 470
Syphilis and HIV: a dangerous combination
Lynn, W., & Lightman, S. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01061-8 · Cited by 450
Hook, E. W. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32411-4 · Cited by 446
2020 European guideline on the management of syphilis
Janier, M., Unemo, M., Dupin, N., Tiplica, G. S., Potočnik, M., & Patel, R. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16946 · Cited by 421
Research works printed but not linked: 26
- Schaudinn F, 1905, Arb Kaiserl Gesurndheisamte, 22, 527
- Schober PC, 1983, Br J Vener Dis, 59, 217
- Anderson J, 1989, Genitourin Med, 65, 239
- Centers for Disease Control and Prevention, 2004, Morb Mortal Wkly Rep, 53, 966
- Prochazka M, Tracking the syphilis epidemic in England: 2010 to 2019. January 2021
- Gjestland T, 1955, Acta Derm Venereol Suppl, 35, 3
- Page M, 2020, Sex Transm Infect, 97, 1
- Larsen SA, 1985, Advances in sexually transmitted diseases, 157
- Izzat NN, 1971, Br J Vener Dis, 47, 162
- Idsoe O, 1972, Bull World Health Organ, 47, 1
- Polnikorn N, 1980, Br J Vener Dis, 56, 363
- Goldmeier D, 1981, Pharmatherapeutica, 3, 14
- Goh BT, 1984, Br J Vener Dis, 60, 371
- Harshan V, 1982, Indian J Dermatol, 27, 119
- Xiao H, 2017, Acta Dermatovenerol Croat, 25, 107
- Steele RW, 1984, Am J Med, 77, 50
- Katsambas A, 1987, Chemioterapia, 6, 549
- Gudjonssen H, 1968, Acta Derm Venereol, 48, 15
- Graciansky PD, 1961, Br J Vener Dis, 37, 247
- Fathilah J, 2003, Med J Malaysia, 58, 437
- Weiner AL, 1951, Ohio Med, 47, 720
- Perdrup A, 1960, Acta Derm Venereol, 40, 340
- Dai T, 2016, Antimicrob Agents Chemother, 61, e01092
- Goldman JN, 1970, Trans Am Acad Ophthalmol Otolaryngol, 74, 509
- Morrison RE, 1985, Genitourin Med, 61, 359
- Patel IH, 1984, Am J Med, 77, 17
Cited by
Acosta-Enriquez, B. G., Huamaní Jordan, O., Morales-Angaspilco, J. E., Campoverde Ventura, G., Ruiz Carrillo, J. A., Blanco- García, L. E., & Huaranga Rivera, L. (2025) · Computers in Human Behavior Reports · doi:10.1016/j.chbr.2025.100829 · Cited by 11
Sethi, V., & Marks, M. (2025) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001404 · Cited by 15
Marra, C. M. (2025) · Brain · doi:10.1093/brain/awaf329 · Cited by 23
Minter, D. J., & Chow, F. C. (2025) · Annals of Neurology · doi:10.1002/ana.78016 · Cited by 12
“25 Data for this approach are quite limited and rely primarily on small retrospective series in patients with neurosyphilis and ocular syphilis.”
Separating Infectious Proctitis from Inflammatory Bowel Disease—A Common Clinical Conundrum
Hall, R., Patel, K., Poullis, A. P., Pollok, R., & Honap, S. (2024) · Microorganisms · doi:10.3390/microorganisms12122395 · Cited by 4
“The treatment of syphilis is with a single intramuscular injection of penicillin G benzathine, 2.4 million units; alternative antibiotics are doxycycline or ceftriaxone [96,106].”
Influential
Metadata
- Authors
- Kingston, M., Apea, V., Evans, C., Fifer, H., Foster, K., Patrick, P., Grant, A., Manns, V., Ramsden, S., Sinka, K., Sukthankar, A., Sullivan, A., & Tyler, S.
- Affiliations
- Manchester University NHS Foundation Trust (GB)
- Barts Health NHS Trust (GB)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- UK Health Security Agency (GB)
- Central and North West London NHS Foundation Trust (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Churchill Hospital (GB)
- Bolton NHS Foundation Trust (GB)
- Corresponding author
- Kingston, Margaret
- Venue
- International Journal of STD & AIDS
- Publisher
- SAGE Publications
- Published
- 2024-09-13
- Volume
- 35
- Issue
- 14
- Pages
- 1142-1160
- ISSN
- 0956-4624 (ISSN-L)
- 1758-1052
- OpenAlex
- W4402545336
- Semantic Scholar
- 4da44a4a295d69dba66d0a7ee651a686accb0df2
- Cited by
- 51
- References
- 124
- Citations by year
- 2026: 31 · 2025: 19 · 2024: 1
- FWCI
- 14.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- International Journal of STD & AIDS (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Syphilis Diagnosis and Treatment
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Life Sciences › Immunology and Microbiology › Parasitology › Vector-borne infectious diseases
- Keywords
- syphilis, syphilis management, pregnant people, children, sexually transmitted infections, treatment guidelines
- MeSH terms
- Anti-Bacterial Agents, Child, Female, United Kingdom, Humans, Pregnancy, Pregnancy Complications, Infectious, Syphilis, Syphilis Serodiagnosis, Treponema pallidum
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BASHH UK guidelines for the management of syphilis 2024. https://app.cochat.ai/papers/10.1177/09564624241280406
- The paper
- Kingston, M., Apea, V., Evans, C., Fifer, H., Foster, K., Patrick, P., Grant, A., Manns, V., Ramsden, S., Sinka, K., Sukthankar, A., Sullivan, A., & Tyler, S. (2024). BASHH UK guidelines for the management of syphilis 2024. International Journal of STD & AIDS. https://doi.org/10.1177/09564624241280406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.